Cite this asPerrotta G (2022) Heart Failure (HF): Recent innovations in clinical therapy and critical profiles of acute and chronic forms. J Cardiovasc Med Cardiol 9(4): 049-076. DOI: 10.17352/2455-2976.000188
Copyright License© 2022 Perrotta G. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background and objectives: Heart failure is a pathological condition characterized by the inability of the heart to pump (cardiac output) an adequate amount of blood to meet the metabolic needs of the body or, at any rate, to be able to do so only at the expense of increased filling pressures in one or more cardiac chambers and the upstream venous circulation. The research group states here the primary objective of expanding the indications contained in the ESC 2021 with the results of the last year on the subject of treatment profiles, to facilitate a better understanding of the overall clinical picture and contribute to the next edition of the guidelines.
Materials and methods: Systematic literature review in the English language from January 1, 2021, to September 30, 2022, on PubMed/MedLine, Web on Science, and Cochrane archive. Our search strategy retrieved 8,317 articles. We excluded books and papers, meta-analyses, reviews, and systematic reviews and selected only 46 studies most significant about the clinical trial and randomized controlled trial.
Results: The recent ESC 2021 guidelines are accurate and timely, and have confirmed their usefulness from a functional perspective, including concerning certain aspects that were represented as a “grey area”. Early risk prediction plays a key role in the subsequent management of patients, and to optimize risk prediction and intensity of management, one should take into account that: a) biomarkers have improved the understanding of the pathophysiology of heart failure and may therefore help to adjust the intensity of management in AHF; b) among the wide variety of biomarkers currently available, NT-proBNP and cTn seem the most promising in this indication; c) among the risk scores described, those combining demographic and clinical parameters with biomarkers in a model with routinely available rapid variables seem the most promising tools; d) in addition to biomarkers, age, systolic blood pressure, respiratory rate, oxygen saturation, creatinine, electrolytes, and blood urea nitrogen are the most commonly used predictor variables in the risk scores described; e) among the models selected, the MEESSI-AHF risk score appears to be currently the most promising tool for predicting the risk of AHF; f) during the management of decompensated patients (and in later stages), the psychological aspect is completely ignored, thus promoting the worsening of psychological symptoms (the need is as evident during the acute episode as it is in the daily management of chronic heart failure).
Conclusions: The scientific literature search enriched the structure of ESC 2021, suggesting its implementation, with other findings related to new drug therapies such as Sotagliflozin, Hydrochlorothiazide Apabetalone, Alprostadil, Empagliflozin, Sacubitril/Valsartan, Dapagliflozin, Sodium-glucose co-transporter-2 inhibitors, and biomarkers such as Urinary sodium (UNa+), IL-6 levels and rh-brain natriuretic peptide (rhBNP), as well as the use of mindful breathing session, osteopathic manipulative treatment, electrical muscle stimulation, low-level tragus stimulation, venoarterial extracorporeal membrane oxygenation, oral nutritional supplements, and the correlative hypothesis between heart failure and intestinal dysbiosis, also concerning the psychological profile. However, these clinical studies suffer from some limitations that will necessarily have to be taken into account, such as the limited size of the population sample selected or the conflict of interest determined by the fact that some research is funded by the same pharmaceutical company producing the drug used that do not necessarily represent a negative limitation on the results obtained from studies.
Heart failure is a pathological condition characterized by the inability of the heart to pump (cardiac output) an adequate amount of blood to meet the metabolic needs of the body or, at any rate, to be able to do so only at the expense of increased filling pressures in one or more cardiac chambers and the upstream venous circulation. Thus, circulatory failure secondary to noncardiac causes (e.g., hypovolemia caused by severe hemorrhage or dehydration) and circulatory congestion resulting from hypervolemia (as occurs in renal failure and states of water overload) cannot be included in the classic definition. Many heart diseases can lead to or evolve into a preclinical or clinical condition of heart failure, and the implementation of certain therapeutic measures can in many cases prevent or delay its development. Moreover, it is possible to reduce the incidence of heart failure in the population also by preventing the development of heart diseases that are its potential causes (for example, ischemic heart disease and hypertension), through the control of risk factors that determine or aggravate them (for example, hypercholesterolemia, hypertriglyceridemia, excessive intake of sodium chloride, alcohol, drugs, smoking, and unhealthy dietary and lifestyle habits) .
Based on these considerations and the idea of a global approach to the problem of heart failure, aimed not only at treatment but also at prevention, a classification of heart failure into four stages has been proposed (Tables 1,2). The first two stages (A and B) include patients who have no evidence (clinical or subclinical) of decompensation, but in whom appropriate interventions may reduce the likelihood that they will develop heart failure in the future; the last two stages (C and D) include, conversely, patients with evidence of decompensation of increasing severity, who require specific types of treatment .
Heart failure is a frequently encountered medical condition. In Europe, the prevalence ranges from 2 to 3%; therefore, approximately 15 million people are affected. A similar number of patients have left ventricular dysfunction in the absence of symptoms of heart failure. The incidence of decompensation in the population increases with age and doubles (or more) per decade from age 40 to 80. It is therefore likely to increase in the future, due both to the lengthening of the average life span of the population and, even more so, the increased life expectancy of patients with various forms of heart disease that can result in decompensation. In adulthood, decompensation is more frequent in men than in women, due to the higher prevalence of ischemic heart disease; however, the difference tends to disappear with the passing of the years .
From a clinical point of view, it is useful to classify the causes of heart failure into two categories (Table 3): 1) underlying (responsible for the pathology); 2) precipitating or triggering (the clinical symptoms). In the first hypothesis (underlying causes), the main cause of myocardial contractility deficit (myocardial insufficiency) and other causes not originating directly from the insufficiency can be included. In the first case, we distinguish clinical causes that primitively involve the myocardium (myocarditis, cardiomyopathies, neuromuscular abnormalities, toxic substances such as cobalt and alcohol, and metabolic causes such as diabetes) from those that involve secondary involvement (ischemia infiltrative pathologies, inflammatory pathologies, systemic pathologies, mechanical alterations, uremia, myocardial depression secondary to drug use, genetic pathologies such as glycogenosis and chronic obstructive pulmonary disease); in the second case, we distinguish instead the conditions that alter ventricular filling (rhythm alterations, myocardial restriction, pericardial constriction, aneurysm, and mitral or tricuspid stenosis) from those that force the heart to face pressure or volume load beyond its capacity (arterial hypertension, aortic stenosis, aortic insufficiency, and shunt). The second hypothesis (precipitating causes), i.e., the causes responsible for the deterioration of myocardial function, can be included those that have a cardiac origin (arrhythmias and negative inotropic drugs) from those that instead have an extracardiac origin (anemia, pregnancy, thyrotoxicosis, infections, pulmonary embolism, hypersodium, emotional stress, physical stress, lack of consistent adherence to drug therapy prescribed in cardiovascular disorders). Heart failure must be distinguished from other forms of circulatory failure (Table 4), in which the function of oxygen transport to tissues is impaired because of an alteration in one (or more) of the other components of the system (blood mass, oxygenated hemoglobin concentration, vascular bed). An example of a clinical picture of circulatory failure that cannot be attributed to myocardial or cardiac failure is, for example, hypovolemic shock from acute hemorrhage. In summary, it must be remembered that myocardial failure, cardiac failure, and circulatory failure are not synonyms, but concepts of increasing scope, each encompassing the preceding ones in a larger family .
Based on symptomatology, the clinical forms of heart failure are divided into [1-3].
Based on the history and objective examination, the healthcare professional can make the diagnosis of heart failure. However, the following instrumental and laboratory tests may facilitate the diagnostic workup [1-3]:
Based on the clinic, several criteria have been proposed for the diagnosis of heart failure [2,3]:
Dyspnea is undoubtedly the most frequent and characteristic symptom of decompensation and consists of a feeling of difficulty in breathing associated with a sensation of air hunger or shortness of breath. It is a consequence of pulmonary congestion, which causes interstitial edema and therefore reduces the distensibility of the lungs and the oxygenation of the blood. This increases the work of the respiratory muscles, which may also be poorly oxygenated due to peripheral hypoperfusion, and contributes to the sensation of breathlessness. In mild or initial cases of decompensation, dyspnea occurs only with intense exertion, or otherwise under conditions requiring increased work and cardiac output. In some patients, in the early stages, a wheezing cough may be the dominant symptom. In more severe cases, dyspnea appears even during mild exertion and, in advanced cases, even at rest. In addition to exertion, in severe cases, dyspnea can appear by simply assuming the supine position, whereby the patient needs to assume or maintain an upright position to breathe normally (a condition called orthopnea). Therefore, when these patients go to bed they are forced to sleep with two or more pillows to avoid the appearance of dyspnea, and those with greater heart failure are sometimes forced to spend entire nights sitting on the bed or in an armchair to avoid or contain dyspnea. The reason that the supine position facilitates the onset of dyspnea lies in the fact that it increases venous return to the heart, thereby facilitating pulmonary congestion. For similar reasons, patients with heart failure may experience sudden episodes of dyspnea during the night (paroxysmal nocturnal dyspnea). In addition to the supine position, other factors may contribute in this case to facilitate the appearance of dyspnea, such as a depression of the center of breath during sleep, which facilitates hypoxia, and the reduction of sympathetic tone, which deprives the myocardium of an important stimulus for its contractile efficiency. In these cases, the patient suddenly wakes up with a sensation of difficulty in breathing and a wheezing and sibilant breath, sometimes accompanied by a wheezing cough. Interstitial edema can compress the bronchioles, causing an increase in airway resistance (cardiac asthma). Typically, the patient sits up in bed with feet dangling or goes to the window in search of air. In mild cases, symptoms improve rapidly withstanding, while in more severe cases they improve only slowly or not at all without therapeutic intervention, especially if there is overt pulmonary edema, which occurs when the pulmonary congestion is such as to cause, in addition to interstitial edema, alveolar edema (see below, Acute pulmonary edema) .
In heart failure, alterations in diuresis are often typical. Diuresis is often contracted during the day, while it frequently improves at night (nocturia), forcing the patient to get up even several times for urination. This behavior derives from the fact that during daytime hours hypoperfusion of the kidney can be important (due to reduced cardiac output), so diuresis is reduced. At night, with the clinostat position, cardiac output increases as a result of the increased venous return; this results in increased renal perfusion, which also improves because of reduced vasoconstriction of the renal arterioles. In more advanced stages of decompensation, renal hypoperfusion becomes constant and produces oliguria (less than 500-600 mL in 24 hours), with increased blood nitrogen and creatinine values. When cardiac output is severely reduced, complete anuria results [2,3].
Cerebral activity symptoms of the altered cerebral function appear only in cases of severe reduction in cardiac output, particularly when severe cerebral vascular alterations coexist. Normally, cardiac output redistribution of cerebral blood flow protects the encephalon from hypoperfusion. When they occur, cerebral symptoms consist of memory loss, difficulty in concentrating, insomnia, and anxiety in chronic cases. In acute cases (pulmonary edema and cardiogenic shock), mental confusion, agitation, drowsiness, and eventually a comatose state is observed .
Drug therapy is decided based on the type of heart failure (whether acute or chronic) and the basis of the main effects, as shown in the following (Table 5):
During the 2021 edition of the recently concluded European Congress of Cardiology, the new European guidelines for the diagnosis and treatment of acute and chronic heart failure were finally awaited. The main novelties of these guidelines can be summarized in eight points [2,3]:
The diagnosis of AHF presupposes initial contact with the healthcare professional, to promptly identify the clinical signs, also with the aid of instruments, such as the electrocardiogram, echocardiography (heart-lung), and chest radiography (in the latter case, especially, if NP test is not available). Then if the diagnosis is uncertain, plasma NP levels (BNP or NT-proBNP or MR-proANP) should be measured; in fact, normal NP concentrations make the diagnosis of AHF unlikely (BNP < 100 pg/ml, NT-proBNP < 300 pg/ml and MR-proANP < 120 pg/ml) Table 7.
The clinical management of the patient with AHF can be divided into three phases (pre-hospital, in-hospital, and pre-discharge), which have different objectives and require different approaches Table 8.
Four major clinical presentations can be described with possible overlaps between them [2,3]:
In the prehospital setting, patients with acute heart failure should benefit from noninvasive monitoring, including pulse oximetry, blood pressure, heart rate, respiratory rate, and a continuous ECG, triggered within minutes of patient contact and in the ambulance if possible. Oxygen therapy can be administered based on clinical judgment, while the search for specific causes (which include hypertension, arrhythmias, valve regurgitation, pulmonary embolism, and infections) must be the starting point to correctly determine the specific therapy [2,3].
The present work intends to focus on the critical aspects related to the diagnostic profiles of heart failure, according to the most recent guidelines, to highlight possible criticalities and gaps not taken into account so far.
Based on what was introduced in the first paragraph of this paper, the research group states here the primary objective of expanding the indications contained in the ESC 2021 with the results of the last year on the subject of treatment profiles, to facilitate a better understanding of the overall clinical picture and contribute to the next edition of the guidelines. Also, the ESC 2021 guidelines, as we will see, have definitively clarified the role of Heart Failure with Mid-Range Ejection Fraction (confirming the independence and nosographic importance) and the role of NT-proBNP (confirming the use and clinical utility). Excluded utility instead for the B-type natriuretic peptide (BNP).
Systematic literature review: we conducted a systematic literature review, considering (inclusion criterion) articles published in the English language from January 1, 2021, to September 30, 2022, that is, all papers that were not considered by ESC 2021 on the topic of heart failure, and therefore all papers before the period and those not related to acute heart failure were excluded (exclusion criterion), to develop a search that could help us find answers to the questions in the objectives section. We performed the literature search in PubMed/MedLine, Web on Science, and Cochrane archive Table 18.
Our search strategy retrieved 8,317 articles. We excluded books and papers, meta-analyses, reviews, and systematic reviews and selected only 46 studies most significant about the clinical trial and randomized controlled trial. An additional 62 manuscripts were then selected to complete related clinical profiles.
In particular, the following profiles emerge from the selected studies:
1. Relative to therapies in heart failure patients
a. In patients with diabetes and recent worsening of heart failure, therapy with sotagliflozin, initiated before or shortly after discharge, resulted in significantly fewer total deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure compared with placebo .
a) Apabetalone treatment was associated with fewer hospitalizations for heart failure in patients with type 2 diabetes and recent acute coronary syndrome .
b) Empagliflozin reduces the risk of hospitalization for heart failure in patients with type 2 diabetes and cardiovascular disease. We sought to elucidate the effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with type 2 diabetes admitted for acute decompensated heart failure. Empagliflozin achieved effective decongestion without an increased risk of worsening renal function as an add-on therapy in patients with type 2 diabetes with acute decompensated heart failure .
c) Urinary sodium (UNa+) has emerged as a useful biomarker of poor clinical outcomes in acute heart failure (AHF). Here, we sought to evaluate: a) the usefulness of a single early determination of UNa+ for predicting adverse outcomes in patients with AHF and renal dysfunction, and b) whether the change in UNa+ at 24 hours (ΔUNa24h) adds any additional prognostic information over baseline values. In patients with AHF and renal dysfunction, a single early determination of UNa+ ≤ 50 mmol/L identifies patients with a higher risk of all-cause mortality and readmission. The ΔUNa24h adds prognostic information over baseline values only when UNa+ at admission is ≤ 50 mmol/L .
d) Although elevated IL-6 levels were associated with higher all-cause mortality in acute HF, no independent association with this outcome was identified at baseline or 30-day measurements. In contrast with prior reports, we did not observe any impact of nesiritide over placebo on serial IL-6 levels .
e) A study aimed to investigate the effects of baseline treatment for heart failure and sequential treatment with rh-brain natriuretic peptide (rhBNP) alone or the combination of rhBNP and sacubitril/valsartan. Cardiac structure, pulmonary artery pressure, inflammation, and oxidative stress in patients with acute heart failure were evaluated. Patients were therefore divided into 3 groups of 100 patients per group: the standard treatment group (treated with an angiotensin-converting enzyme inhibitor, a β-receptor blocker, and a corticosteroid antagonist), the rhBNP group (baseline treatment combined with rhBNP), and the sequential treatment group (baseline heart failure treatment combined with rhBNP followed by sacubitril/valsartan). Changes in NT-pro brain natriuretic peptide (BNP) levels, cardiac troponin T (cTnT) levels, cardiac structure, pulmonary artery pressure, and levels of inflammatory and oxidative stress factors were compared between the 3 groups at 1, 4, 12, and 36 weeks after treatment. The sequential treatment group showed superior results compared with the standard treatment group and the rhBNP group in terms of left atrium diameter, left ventricular end-diastolic volume, left ventricular ejection fraction, pulmonary artery pressure, NT-proBNP levels, and cTnT levels, which respond to damage to the structure of the heart and myocardium. This finding may be related to decreased levels of inflammatory factors and correction of the oxidative stress imbalance. Sacubitril/valsartan significantly reduced serum levels of inflammatory factors in patients with acute heart failure while decreasing levels of oxidant factors and increasing levels of antioxidant factors. These changes may be one explanation for the improved cardiac structure and pulmonary artery pressure observed in the sequential treatment group .
f) Treatment with sodium-glucose co-transporter-2 inhibitors induces an initial 3-5 ml/min/1.73 m2 decline in the estimated glomerular filtration rate (eGFR). Although considered to be of hemodynamic origin and largely reversible, this ‘eGFR dip’ may cause concern in clinical practice, which highlights the need to better understand its incidence and clinical implications. In this post hoc analysis of the EMPA-REG OUTCOME trial, 6,668 participants randomized to empagliflozin 10 mg, 25 mg, or placebo with eGFR available at baseline and week four were categorized by initial eGFR change into three groups; over 10% decline (‘eGFR dipper’), over 0 and up to 10% decline (‘eGFR intermediate’), no eGFR decline (‘eGFR non-dipper’). Baseline characteristics of ‘eGFR intermediate’ and ‘eGFR non-dipper’ were generally comparable. An initial ‘eGFR dip’ was observed in 28.3% of empagliflozin versus 13.4% of placebo-treated participants; odds ratio 2.7 [95% Confidence Interval 2.3-3.0]. In multivariate logistic regression, diuretic use and higher KDIGO risk category at baseline were independently predictive of an ‘eGFR dip’ in empagliflozin versus placebo. The safety and beneficial treatment effects of empagliflozin on cardiovascular and kidney outcomes were consistent across subgroups based on these predictive factors. The initial ‘eGFR dip’ did not have a major impact on the treatment effect of empagliflozin on subsequent cardiovascular death, hospitalization for heart failure, and incident or worsening kidney disease. Thus, patients with type 2 diabetes with more advanced kidney disease and/or on diuretic therapy were more likely to experience an ‘eGFR dip’ of over 10% with empagliflozin, but the reduction in cardiovascular and kidney outcomes was not relevantly modified by such ‘eGFR dip.’ .
g) Adding hydrochlorothiazide to the usual treatment of patients with acute decompensated heart failure did not cause a significant difference in daily body weight reduction compared to placebo. In an analysis adjusted to the dose of intravenous furosemide, adding HCTZ 50 mg to furosemide resulted in a significant synergistic effect on weight loss .
h) Hospitalization for acute decompensated heart failure (ADHF) remains a major source of morbidity and mortality. The current study aimed to investigate the feasibility, safety, and efficacy of outpatient furosemide intravenous (IV) infusion following hospitalization for ADHF. The use of a standardized protocol of outpatient IV furosemide infusion for one month following hospitalization for ADHF was found to be safe and efficacious in reducing 30-day re-hospitalization .
i) This study aimed to explore the rapid effects of dapagliflozin in heart failure with reduced ejection fraction (HFrEF). After 2 weeks, while multiple parameters supported BP reduction and haemoconcentration with dapagliflozin, reduction in cardiac filling pressure, lung water, and functional improvement were not shown. Reduced ventricular ectopic burden suggests an early antiarrhythmic benefit. The small increase in troponin T and the reduction in the reactive hyperemia index warrant further mechanistic exploration in this treatment of proven mortality benefits in HFrEF .
j) We sought to compare the effects of furosemide + hypertonic saline solution (HSS) treatment in patients with acute decompensated heart failure in comparison with furosemide alone and the response in a compensated state after an acute saline load about serum levels of heart failure biomarkers. Our findings concerning a comparable degree of reduction in the serum levels of three cardinal biomarkers indicate that a reduction in serum heart failure markers is not linked to a higher degree of congestion relief with a more rapid achievement of a clinical compensation state. This issue may have possible benefits on clinical practice concerning its therapeutic effects over and beyond the simple amelioration of clinical congestion signs and symptoms. Nevertheless, our findings of higher delta values after treatment with i.v. furosemide plus HSS indicates a possible higher efficacy using modulation of the stretching and fibrosis mechanisms .
k) Associations between growth differentiation factor-15 (GDF-15), cardiovascular outcomes, and exercise capacity among patients with a recent hospitalization for heart failure (HHF) and heart failure with reduced ejection fraction (HFrEF) are unknown. We utilized data from the ‘Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT) study to address these knowledge gaps. An increase in GDF-15 over 30 days among patients in HFrEF was independently associated with an increased risk of cardiovascular events and declining exercise capacity. These results support the value of longitudinal GDF-15 trajectory in informing the risk of heart failure disease progression .
l) In older patients with hypertension, intensive treatment with a systolic blood-pressure target of 110 to less than 130 mm Hg resulted in a lower incidence of cardiovascular events than standard treatment with a target of 130 to less than 150 mm Hg .
m) In patients stabilized during hospitalization for acute decompensated heart failure (HF), initiation of sacubitril/valsartan compared with enalapril decreased the risk of cardiovascular death or rehospitalization for HF without increasing the risk of adverse events. It is unknown whether potentially high-risk subpopulations have a similar risk-benefit profile. In high-risk subpopulations admitted for acute decompensated HF, treatment with sacubitril/valsartan after initial stabilization conferred a consistent reduction in cardiovascular death or rehospitalization for HF and was well tolerated .
n) Dapagliflozin administration in T2D (patients with type 2 diabetes) resulted in a both acute and chronic reduction in systolic blood pressure, a reduction in vasoconstrictors, and an increase in vasodilators. These changes may potentially contribute to its antihypertensive effects and its benefits in congestive cardiac failure .
2. Relative to therapies in patients with cardiorenal syndrome
In patients with acute heart failure, empagliflozin increased fractional glucose excretion and plasma osmolality, without affecting fractional sodium excretion or urine osmolality and caused a temporary decline in estimated glomerular filtration rate. This suggests that empagliflozin stimulates osmotic diuresis through increased glycosuria rather than natriuresis in patients with acute heart failure .
Ultrafiltration therapy is safe and can improve diuretic sensitivity in heart failure patients with reduced ejection fraction and diuretic resistance .
Although the reno-protective effects of sodium-glucose cotransporter 2 inhibitors are known in patients with heart failure or type 2 diabetes mellitus (T2DM), this effect has not been confirmed in patients with acute myocardial infarction (AMI). Empagliflozin prevented kidney function decline in patients with AMI and T2DM, especially those with baseline eGFR ≥ 60 mL/min/1.73 m2. Early administration of sodium-glucose cotransporter 2 inhibitors in these patients is considered desirable for renal protection .
. Relative to psychological therapies in patients with heart failure
a) Standard treatment of heart failure includes pharmacotherapy and cardiac device implantation. However, supportive approaches in the management of dyspnea in heart failure are limited. A parallel-group, unblinded, randomized controlled trial of a single 20-minute mindful breathing session compared with standard care alone among patients hospitalized for moderate to severe dyspnea due to acute decompensated heart failure demonstrated a statistically significant reduction in dyspnea in the intervention group compared with the control group at minute 20, and therefore according to these results, it can be argued that a single 20-minute mindful breathing session is effective in reducing dyspnea for patients in acute decompensated heart failure .
b) Patients with chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF) are at high risk of readmission after hospital discharge. There is conflicting evidence however on whether timely follow-up with a primary care provider reduces that risk. The objective of this study is to understand the perspectives of patients with COPD and CHF, and their caregivers, on the role of primary care provider follow-up after hospital discharge. Patients and caregivers valued in-person follow-up with their primary care provider the following discharge from the hospital because of the trust established through pre-existing longitudinal relationships. Our results suggest policymakers should focus on improving rates of primary care provider attachment and systems supporting informational continuity .
4. Relative to therapies in patients with myocardial infarction
a) For patients with clinically defined heart failure following acute myocardial infarction, ramipril results in a sustained survival benefit and is associated with an extension of the life of up to 14.5 months for, on average, 13 months of treatment duration .
b) Myocardial infarction with non-obstructive coronary arteries (MINOCA) is common and occurs in 6-8% of all patients fulfilling the diagnostic criteria for acute myocardial infarction (AMI). This work describes the rationale behind the trial ‘Randomized Evaluation of Beta Blocker and ACE-Inhibitor/Angiotensin Receptor Blocker Treatment (ACEI/ARB) of MINOCA patients’ (MINOCA-BAT) and the need to improve the secondary preventive treatment of MINOCA patients. METHODS: MINOCA-BAT is a registry-based, randomized, parallel, open-label, multicenter trial with a 2:2 factorial design. The primary aim is to determine whether oral beta blockade compared with no oral beta-blockade, and ACEI/ARB compared with no ACEI/ARB, reduce the composite endpoint of death of any cause, readmission because of AMI, ischemic stroke, or heart failure in patients discharged after MINOCA without clinical signs of heart failure and with left ventricular ejection fraction ≥40%. A total of 3500 patients will be randomized into four groups; e.g. ACEI/ARB and beta blocker, beta blocker only, ACEI/ARB only, and neither ACEI/ARB nor beta blocker, and followed for a mean of 4 years. While patients with MINOCA have an increased risk of serious cardiovascular events and death, whether conventional secondary preventive therapies are beneficial has not been assessed in randomized trials. There is a limited basis for guideline recommendations in MINOCA. Furthermore, studies of routine clinical practice suggest that the use of secondary prevention therapies in MINOCA varies considerably. Thus results from this trial may influence future treatment strategies and guidelines specific to MINOCA patients .
c) In patients with symptomatic heart failure, sacubitril-valsartan has been found to reduce the risk of hospitalization and death from cardiovascular causes more effectively than an angiotensin-converting enzyme inhibitor. Trials comparing the effects of these drugs in patients with acute myocardial infarction have been lacking. Sacubitril-valsartan was not associated with a significantly lower incidence of death from cardiovascular causes or incident heart failure than ramipril among patients with acute myocardial infarction .
d) In patients with coronary heart disease (CHD), atrial fibrillation (AF) is associated with increased morbidity and mortality. We investigated the associations between clinical risk factors and biomarkers with incident AF in patients with CHD. In patients with optimally treated CHD, the incidence of new AF was 1.2% per year. Age, NT-proBNP as a marker of impaired cardiac function, and BMI were the strongest factors, independently and consistently associated with incident AF. Male sex and low physical activity may also contribute to the risk of AF in patients with CHD .
e) Innate lymphoid cells type 2 (ILC2s) play critical homeostatic functions in peripheral tissues. ILC2s reside in perivascular niches and limit atherosclerosis development. ILC2s promote cardiac healing and improve the recovery of heart function after Myocardial Infarction (MI) in mice. Activation of ILC2 using low-dose IL-2 could be a novel therapeutic strategy to promote a reparative response after MI .
f) Thyroid dysfunction contributes to adverse events in several types of cardiovascular diseases. The present study aims to determine whether thyroid status is associated with the prognosis of patients with acute myocardial infarction (AMI). Compared with euthyroid status, hypothyroid status has an independent predicting value for adverse cardiovascular events in AMI patients. Further investigations are required to illustrate whether treatment of thyroid dysfunction could improve the prognosis of AMI patients .
g) Alprostadil can effectively dilate blood vessels, improve cardiac microcirculation, and reduce cardiac load. Tanshinone IIa injection can protect against atherosclerosis and reduce myocardial oxygen consumption. However, the effects of alprostadil combined with tanshinone IIa injection on microcirculation disorder, outcomes, and cardiac function in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI) are still not fully clear. For AMI patients after PCI, alprostadil combined with tanshinone IIa injection can effectively improve microcirculation and ventricular remodeling, improve cardiac function and reduce the occurrence of MACEs. This combination can be widely used in clinical practice .
h) It is unknown when to start anticoagulation after acute ischemic stroke (AIS) from atrial fibrillation (AF). Early anticoagulation may prevent recurrent infarctions but may provoke hemorrhagic transformation as AF strokes are typically larger and hemorrhagic transformation-prone. Later anticoagulation may prevent hemorrhagic transformation but increases the risk of secondary stroke in this time frame. I aimed to compare early anticoagulation with apixaban in AF patients with stroke or transient ischemic attack (TIA) versus warfarin administration at later intervals. Early initiation of anticoagulation after TIA, small-, or medium-sized AIS from AF does not appear to compromise patient safety. The potential efficacy of early initiation of anticoagulation remains to be determined from larger pivotal trials .
5. Relative to therapies in patients with COVID-19-related issues and vaccines in general
a) Among patients hospitalized with mild to moderate COVID-19 and who were taking ACEIs or ARBs before hospital admission, there was no significant difference in the mean number of days alive and out of the hospital for those assigned to discontinue vs. continue these medications. These findings do not support routinely discontinuing ACEIs or ARBs among patients hospitalized with mild to moderate COVID-19 if there is an indication for treatment .
b) In patients with high-risk cardiovascular disease, high-dose trivalent inactivated influenza vaccine, compared with standard-dose quadrivalent inactivated influenza vaccine, did not significantly reduce all-cause mortality or cardiopulmonary hospitalizations. Influenza vaccination remains strongly recommended in this population .
6. Relative to therapies in patients with respiratory failure
a) Respiratory failure during an index hospitalization for acute HF was associated with increased rehospitalization and all-cause mortality. The development of respiratory failure during an acute HF admission identifies a particularly vulnerable population, which should be identified for closer monitoring .
b) Sigh is a cyclic brief recruitment maneuver: previous physiologic studies showed that its use could be an interesting addition to pressure support ventilation to improve lung elastance, decrease regional heterogeneity, and increase the release of surfactant. Among hypoxemic intubated intensive care unit patients, the application of sigh was feasible and without increased risk .
c) Chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) are characterized by severe symptom burden and common acute worsening episodes that often require hospitalization and affect prognosis. Although many studies have shown that person-centered care (PCC) increases self-efficacy in patients with chronic conditions, studies on patients with COPD and CHF treated in primary care and the effects of PCC on the risk of hospitalization in these patients are scarce. PCC using a combined digital platform and structured telephone support seems to be an option to increase the short-term self-efficacy of people with COPD and CHF. This study adds to the knowledge of conceptual innovations in primary care to support patients with COPD and CHF .
d) In patients presenting to the ED with acute cardiogenic pulmonary edema or decompensated COPD, hCPAP was non-inferior to fCPAP and resulted in greater comfort levels and lower intubation rate .
e) In patients with heart failure (HF), the exhaled concentrations of hydrogen after a breath test (a non-invasive assessment of small intestinal overgrowth) have been related to HF severity and higher risk of adverse outcomes. Indeed, two intestinal bacterial metabolites-blood Trimethylamine N-Oxide (TMAO) and butyrate-have been related to a worse prognosis in HF. However, the relationship between the exhaled concentrations of hydrogen after a breath test and these two metabolites remains unknown. Thus, in this post-hoc analysis, we sought to evaluate whether these two metabolites are associated with the exhaled concentrations of hydrogen after a breath test in patients with a recent admission for HF. We included 60 patients with a recent hospitalization for HF. Cumulative hydrogen over time was integrated into a single measurement by the area under the concentration curve (AUC-H2). A linear regression multivariable analysis was used to evaluate the associations. A 2-sided p-value < 0.05 was considered to be statistically significant. The median (p25-p75) amino-terminal pro-brain natriuretic peptide, AUC-H2, TMAO, and Butyrate were 4789 pg/ml (1956-11149), 1615 (700-2585), 0.68 (0.42-1.12), and 0.22 ± 13, respectively. After multivariate adjustment, TMAO and butyrate were significantly associated with AUC-H2 (p = 0.027 and p = 0.009, respectively). For TMAO, this association was positive, and for butyrate, negative. Bacterial-origin metabolites TMAO and Butyrate were independently related to AUC-H2 in patients with a recent hospitalization for acute HF . These results confirm the importance of the correlation between intestinal dysbiosis and heart failure .
f) Acute respiratory distress syndrome (ARDS) is an increasingly common acute respiratory failure that seriously threatens people’s health. ARDS has a case fatality rate of up to 40%. ARDS is a serious threat to the life safety of patients and their quality of life, causing a huge economic burden to individuals, families, and society. ARDS has become a large worldwide public health problem. Prone position ventilation (PPV) is an important auxiliary treatment for ARDS, which could improve oxygenation. However, PPV could cause Pressure injuries (PI) and other complications easily. We found that 45° PPV could reduce the incidence of PI, but lack of robust Evidence-based medicine evidence proving its efficacy. Therefore, we designed a randomized controlled trial to evaluate the efficacy of 45° PPV in the treatment of ARDS. 45° PPV may reduce the incidence of PI and improve oxygenation in patients with ARDS, which has important value in practical application .
7. Relative to therapies in cardiological patients and osteopathic manipulations, electrical muscle stimulation and other functions
a) Osteopathic manipulative treatment modulates both the vascular and autonomic nervous system (ANS) in healthy volunteers. However, the acute and time-course effects of the OMT on patients with an overactive ANS remain unclear. Osteopathic manipulative treatment was effective at increasing brachial blood flow and stimulating the vagal system in patients with heart failure. Moreover, vascular changes seem to precede autonomic modulation .
b) Reduced aerobic capacity and deconditioning contribute to morbidity and mortality in elderly acute heart failure (AHF) patients. Electrical muscle stimulation (EMS) is a suitable alternative to exercise in AHF. However, feasibility and efficacy are unknown in a real-world setting. Changes in 6-MWTD suggest the efficacy of EMS. Whereas all tolerated EMS well, the burden of study intervention was too high and resulted in a consent rate of < 50% and high dropouts, which limit the interpretability of our data. Less demanding EMS protocols are required to evaluate the full potential of EMS in elderly AHF patients .
c) Older patients who are hospitalized for acute decompensated heart failure have high rates of physical frailty, poor quality of life, delayed recovery, and frequent rehospitalizations. Interventions to address physical frailty in this population are not well established. In a diverse population of older patients who were hospitalized for acute decompensated heart failure, an early, transitional, tailored, progressive rehabilitation intervention that included multiple physical-function domains resulted in greater improvement in physical function than usual care .
d) Autonomic dysregulation in heart failure with reduced ejection fraction plays a major role in endothelial dysfunction. Low-level tragus stimulation (LLTS) is a novel, noninvasive method of autonomic modulation. Our study demonstrated the beneficial effects of acute neuromodulation on macrovascular function. Larger studies to validate these findings and understand mechanistic links are warranted .
e) Deterioration of nutritional status during hospitalization in patients with chronic heart failure increases mortality. Whether nutritional support during hospitalization reduces these risks, or on the contrary, may be harmful due to an increase in salt and fluid intake, remains unclear. Among hospitalized patients with chronic heart failure at high nutritional risk, individualized nutritional support reduced the risk for mortality and major cardiovascular events compared with standard hospital food. These data support malnutrition screening upon hospital admission followed by an individualized nutritional support strategy in this vulnerable patient population .
f) Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly being used in circulatory failure. The main indications are cardiogenic shock, post-cardiotomy cardiac failure, and refractory cardiac arrest. However, VA-ECMO weaning is particularly challenging, and weaning failure is reported to be as high as 50%, with increased related mortality. Levosimendan is a novel long-acting effect indicator used in cardiogenic shock and terminal heart failure decompensation. Levosimendan use in VA-ECMO patients seems to reduce weaning failure regardless of the initial etiology and to reduce mortality when administrated early after VA-ECMO initiation. However, studies are limited to retrospective analyses and reported case series. The WEANILEVO trial aims to evaluate whether the administration of levosimendan before VA-ECMO weaning is associated with reduced rates of weaning failure and recourse to other temporary circulatory support. Levosimendan use in VA-ECMO appears to be beneficial for reducing weaning failure and mortality. The results of WEANILEVO should significantly influence decisions regarding the use of levosimendan for VA-ECMO weaning .
g) Oral Nutritional Supplements (ONS) are used to treat malnutrition and improve clinical outcomes in malnourished patients. Poor handgrip strength (HGS) is associated with an increased risk of mortality, disability, and other adverse health consequences. S-ONS provided during hospitalization and up to 90 days post-discharge improves HGS in malnourished older adults following cardiovascular and pulmonary events and may contribute to improvement in the patient’s overall recovery .
Heart failure with intermediate ejection fraction (HFmrEF) is a new category of heart failure (HF), between HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). Earlier studies were conducted primarily in HFrEF patients with a left ventricular ejection fraction (LVEF) of less than 35%-40%; later, HFpEF captured the spotlight of the research field, and studies focused on patients with HF symptoms but with an LVEF greater than 50%. As a result, a knowledge gap has arisen that includes LVEF between 40 and 49%. Current studies focusing on patients with HFmrEF are supporting the same conclusions or even have contradictory results. HFmrEF has a prevalence of 10-20% of patients with HF. HFmrEF has distinct but intermediate clinical, structural, and functional characteristics and intermediate outcomes compared to HFrEF and HFpEF . However, there is still a large void of evidence regarding detailed hemodynamic features, long-term follow-up, and optimal treatment options for these patients, although the ESC 2021 guidelines confirm and solidify this distinction.
Subsequent studies also confirm this direction, arguing that:
B-type natriuretic peptide (BNP) or NT-proBNP?
B-type natriuretic peptide (BNP) has favorable effects on left ventricular remodeling, including antifibrotic and antiapoptotic properties. We tested the hypothesis that infusion of BNP after an acute myocardial infarction would reduce left ventricular systolic and diastolic volumes and improve left ventricular ejection fraction compared with placebo. Infusion of BNP in patients with an anterior myocardial infarction did not affect parameters of left ventricular remodeling. Patients treated with BNP who had a baseline left ventricular ejection fraction of < 40% had a trend towards reduced left ventricular infarction size compared with placebo. These results do not support the use of intravenous BNP in patients after recent myocardial infarction  as previously supported by other research .
B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) aid in the diagnosis of heart failure (HF) and the determination of patient prognosis. In response to a myocardial wall stretching, pre-proBNP is synthesized and transformed into proBNP; which is further transformed into the biologically inactive fragment NT-proBNP and the biologically active fragment BNP. Because BNP and NT-proBNP are elevated in patients with HF, both are useful adjuncts to clinical evaluation. However, measurable concentrations of NT-proBNP are higher in plasma than BNP, necessitating different clinical cut-points; consequently, clinical guidelines give no guidance to clinicians or laboratories regarding the best natriuretic peptide to test for HF evaluation . Despite widespread recognition that these tests are essentially clinically equivalent, no published study has evaluated the diagnostic concordance between BNP and NT-proBNP to exclude or rule out HF at accepted cut points. To fill this gap in the literature, one study performed BNP and NT-proBNP testing on 3,029 BNP patient samples, assigning patients to two groups (acute HF and non-acute HF) It was found that there were frequent occasions when patients would be excluded for HF by one method and excluded for HF by the other; in addition, chronic kidney disease was found to have a profound negative impact on concordance between the two tests . What this study, in short, highlights are the multiple biological and analytical complexities associated with natriuretic peptide immunoassays. There are multiple, well-known problems with the measurement of BNP and NT-proBNP in patient samples, including differences in protein glycosylation, half-life, renal clearance, biochemical diversity in HF patients, and variable antibody reactivity with the proBNP precursor .
Consequently, BNP and NT-proBNP are not interchangeable. However, further studies are needed to examine the diagnostic concentrations of natriuretic peptides, clearance patterns, and specificity of the assay for circulating forms. The differences between BNP and NT-proBNP at the biological level relate to the fact that one is biologically active as a hormone, BNP, whereas NT-proBNP is passively eliminated from the body and is not biologically active. Therefore, BNP has a much shorter half-life, and NT-proBNP has a longer half-life. NT-proBNP, as a result, circulates in higher concentrations in the bloodstream, which means, therefore, it is more likely to be more sensitive to detect earlier forms of heart failure because it circulates at somewhat higher levels. When you look at their diagnostic and prognostic capabilities, they are largely similar. But I would say that when we look at the value of these markers for patient management, for therapy monitoring, clearly NT-proBNP has substantially more data behind its use. Also, with the emergence of new therapies for heart failure, particularly the ARNi class of heart failure therapies, this class of drugs affects BNP concentrations because it blocks BNP breakdown, which means that BNP concentrations will increase substantially in patients treated with ARNis, whereas NT-proBNP values are not affected, as on the other hand already sustained in the past [57,58] and in the current future .
Acute heart failure (AHF) is a complex and heterogeneous syndrome associated with an alarming increase in incidence and still unacceptably high rates of mortality and morbidity. Because this dismal outcome is at least in part due to a mismatch between the severity of AHF and the intensity of its management, both in the hospital and immediately after discharge, early and accurate risk prediction could contribute to more effective and risk-adjusted management. Biomarkers, in this role, are noninvasive and highly reproducible quantitative tools that have improved the understanding of the pathophysiology of AHF.
Better risk prediction using clinical risk scores or biomarkers could contribute to more effective risk-adjusted management. Thus, high-risk patients could be transferred to an intensive care unit with continuous monitoring (marked in red), intermediate-risk patients could be admitted or treated temporarily in an intermediate care unit (marked in yellow), and low-risk patients could be safely discharged home with adapted outpatient follow-up (marked in green).
Early risk prediction plays a key role in the subsequent management of patients presenting with AHF, a heterogeneous syndrome associated with still unacceptably high rates of mortality and morbidity. To optimize risk prediction and intensity of management, clinicians should be aware of the following concepts:
a) Biomarkers have improved understanding of the pathophysiology of heart failure and may therefore help to adjust the intensity of management in AHF.
b) Among the wide variety of biomarkers currently available, natriuretic peptides can seem the most promising in this indication.
c) As a heterogeneous syndrome with various phenotypes, a biomarker approach alone is insufficient for accurate risk prediction in AHF. Heart failure risk scores that combine several predictor variables are more promising to help clinicians make decisions and personalize the intensity of management.
d) Among the risk scores described, those that combine demographic and clinical parameters with biomarkers in a model with routinely available fast variables seem the most promising tools for early and accurate risk stratification in the emergency department.
e) For early risk stratification of patients with AHF in the emergency department, scores that have been specifically derived and validated in emergency department cohorts should preferably be used.
f) In addition to biomarkers, age, systolic blood pressure, respiratory rate, oxygen saturation, creatinine, electrolytes, and blood urea nitrogen are the most commonly used predictive variables in the risk scores described.
g) Among the selected models, the MEESSI-AHF risk score currently appears to be the most promising tool for AHF risk prediction. This score was developed in the emergency department in a large derivation cohort, consists of fast and routinely available variables that show very accurate risk prediction, and has been externally validated in a country other than the one in which it was developed.
During the management of decompensated patients (and in later stages), the psychological aspect is completely ignored, with cardiological and systemic management of the HF sufferer being a priority , actually promoting a worsening of psychological symptoms resulting from the traumatic event but also previous morbid conditions. The need is as evident during the acute episode as it is in the daily management of chronic heart failure.
The adverse clinical event determines a significant increase in anxiety symptomatology [63,64], capable of decompensating the patient or aggravating his or her psychopathological picture , whether neurotic , border [67-70], or psychotic [71,72].
It has been noted that, throughout the hospitalization period, the disease state is capable of generating marked anxiety and depressive symptoms [73,74], which are then capable of fostering or aggravating neurotic conditions from the traumatic cardiac event  such as obsessive and somatic disorders, avoidant behaviors, sleep-wake rhythm alterations, panic attacks, and behavioral addictions, to more or less structured suicidal ideations [76-83], as a result of one’s emotional perception and one’s ability to interpret the plane of reality [84-88].
Therefore, deepening the patient’s inner human dimension is a fundamental clinical necessity, to ensure a holistic intervention capable of making him feel protected, especially after the traumatic cardiac event, with the help of a clinical psychological interview and, if necessary, a structured intervention with textual tools capable of investigating both the personality framework and its inner dimensions (ego defense mechanisms and sexual matrix) [89-104], to foster in the patient the need to regain his human dimension of serenity and harmony [105-107].
The ESC 2021 guidelines are a landmark in cardiology and represent the state of the art in science; therefore, the need to constantly update them represents a fundamental utility.
Already, the 2021 edition has introduced important innovations, especially in terms of changes in the criteria for chronic heart failure, in terms of the use of strategies and new pharmacological products and first-line drugs, in terms of phenotypic reconnaissance, in terms of electrical therapy, in terms of implementation of telemedicine and follow-up, and terms of reclassification of acute heart failure, but precisely based on what was introduced in the first paragraph of this paper, the research group states here the primary objective of expanding the indications contained in the ESC 2021 with the results of the last year on the subject of treatment profiles, to facilitate a better understanding of the overall clinical picture and contribute to the next edition of the guidelines.
Also, the ESC 2021 guidelines, as we will see, have definitively clarified the role of Heart Failure with Mid-Range Ejection Fraction (confirming the independence and nosographic importance) and the role of NT-proBNP (confirming the use and clinical utility). Excluded utility instead for the B-type natriuretic peptide (BNP) Table 19.
The ESC 2021 guidelines are a landmark in cardiology The scientific literature search enriched the structure of ESC 2021, suggesting its implementation, with other findings related to new drug therapies such as Sotagliflozin, Hydrochlorothiazide Apabetalone, Alprostadil, Empagliflozin, Sacubitril/Valsartan, Dapagliflozin, Sodium-glucose co-transporter-2 inhibitors, and biomarkers such as Urinary sodium (UNa+), IL-6 levels and rh-brain natriuretic peptide (rhBNP), as well as the use of mindful breathing session, osteopathic manipulative treatment, electrical muscle stimulation, low-level tragus stimulation, venoarterial extracorporeal membrane oxygenation, oral nutritional supplements, and the correlative hypothesis between heart failure and intestinal dysbiosis [39,108], also concerning psychopathological profiles.
However, these clinical studies suffer from some limitations that will necessarily have to be taken into accounts, such as the limited size of the population sample selected or the conflict of interest determined by the fact that some research is funded by the same pharmaceutical company producing the drug users that do not necessarily represent a negative limitation on the results obtained from studies.
All data generated or analyzed during this study are included in this published article [and its supplementary information files].
Subscribe to our articles alerts and stay tuned.